(R)-4-氧代-1,2,3,4-四氢萘-2-羧酸 | 113867-23-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: (R)-4-氧代-1,2,3,4-四氢萘-2-羧酸
• 英文名称: (R)-4-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
• 英文别名: (2R)-4-oxo-2,3-dihydro-1H-naphthalene-2-carboxylic acid
• CAS: 113867-23-5
• 化学式: C₁₁H₁₀O₃
• 分子量: 190.199
• InChiKey: UYNMKOITXUEVCZ-MRVPVSSYSA-N

物化性质

• 沸点：
  393.3±31.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  (R)-4-氧代-1,2,3,4-四氢萘-2-羧酸 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 、 氯仿 为溶剂， 反应 16.0h， 生成 (3R)-3-(羟基甲基)-3,4-二氢-1(2H)-萘酮
  参考文献：
  名称：

  （R）-（-）-和（S）-（+）-3-羟甲基-1-四氢萘酮甲苯磺酸盐的制备，这些化合物是通过拆分前体来合成新的中枢神经系统药物的关键中间体

  摘要：

  （R）-（-）-和（S）-（+）-3-羟甲基-1-四氢萘基甲苯磺酸酯的制备是通过经典决议或脂肪酶催化其前体之一的动力学拆分。

  DOI：

  10.1016/s0957-4166(02)00822-4
• 作为产物：
  描述：

  R-2-苄基琥珀酸 在 硫酸 作用下， 反应 8.0h， 生成 (R)-4-氧代-1,2,3,4-四氢萘-2-羧酸
  参考文献：
  名称：

  （R）-（-）-和（S）-（+）-3-羟甲基-1-四氢萘酮甲苯磺酸盐的制备，这些化合物是通过拆分前体来合成新的中枢神经系统药物的关键中间体

  摘要：

  （R）-（-）-和（S）-（+）-3-羟甲基-1-四氢萘基甲苯磺酸酯的制备是通过经典决议或脂肪酶催化其前体之一的动力学拆分。

  DOI：

  10.1016/s0957-4166(02)00822-4

文献信息

• [EN] ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS<br/>[FR] COMPOSÉS D'ARYLALKYLAMINE JOUANT LE RÔLE DE MODULATEURS DES RÉCEPTEURS SENSIBLES AU CALCIUM
  申请人：LUPIN LTD

  公开号：WO2014033604A1

  公开（公告）日：2014-03-06

  The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I)

  本发明提供了作为钙感应受体调节剂（CaSR）的芳烷基胺化合物。特别是，本发明的化合物可用于治疗、管理或减轻与调节钙感应受体（CaSR）相关疾病、障碍、综合征和/或症状的严重性。本发明还提供了包含这些化合物的药物组合物，以及用于治疗、管理或减轻与调节CaSR相关的疾病、障碍、综合征和/或症状的方法。本发明还涉及制备本发明化合物的方法。（公式I）
• 2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
  申请人：Sher M. Philip

  公开号：US20060111338A1

  公开（公告）日：2006-05-25

  Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R 1 , R 2 , X and Z are defined herein.

  提供了一些新的化合物，它们是糖原磷酸化酶抑制剂，可用于治疗、预防或减缓需要糖原磷酸化酶抑制剂治疗的疾病，如糖尿病及相关疾病（如高血糖、糖耐量受损、胰岛素抵抗和高胰岛素血症），与糖尿病相关的微血管并发症（如视网膜病变、神经病变、肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病，如动脉粥样硬化、心脏功能异常、心肌缺血和中风），以及代谢综合征及其组成疾病，包括高血压、肥胖和脂质代谢异常（包括高三酸甘油酯血症、高胆固醇血症和低高密度脂蛋白血症），以及其他疾病，如非心脏缺血、感染和癌症。这些新的化合物具有特定的结构、立体异构体、前药或其药用可接受的盐，其中W、R1、R2、X和Z在此处有定义。
• Comparison of Deacylation Rates of Chymotryptic Catalysis within an Enantiomeric Pair of p-Nitrophenyl Esters.
  作者：Kazutaka TANIZAWA、Hiroyuki YAMADA、Kunihiko ITOH、Yuichi KANAOKA

  DOI：10.1248/cpb.39.2748

  日期：——

  p-Nitrophenyl esters carrying a chiral acyl group were synthesized. These compounds were shown to meet the requirements of chymotrypsin for the specific binding and the acylation. Therefore, the behavior of p-nitrophenyl esters with chymotrypsin is considered to be virtually identical to that of p-amidinophenyl esters with trypsin which were proposed as "inverse substrates" for the enzyme. These esters, derived from each pair of enantiomers, have been successfully used for the analysis of enantiomeric preference of chymotrypsin at the deacylation stage. The chiral requirement of the enzyme active site for the catalytic efficiency was discussed.

  合成了带有手性酰基的对硝基苯基酯。这些化合物被证明符合胰蛋白酶在特定结合和酰化方面的要求。因此，认为对硝基苯基酯与胰蛋白酶的作用几乎与对氨基苯基酯与胰酶的作用相同，后者被提议作为该酶的“逆底物”。这些酯源自每对对映体，已成功用于分析胰蛋白酶在去酰化阶段的对映体偏好。讨论了酶活性位点对催化效率的手性需求。
• Novel compounds
  申请人：SmithKline Beecham SpA

  公开号：US20040024218A1

  公开（公告）日：2004-02-05

  Compounds of formula I, or a salt thereof or a hydrate thereof, as follows: 1 wherein X and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, aryl, heterocyclyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo; m and n are independently 0 to 3, provided that m and n are not both 0; A represents a single bond or is —(CR pa R pb ) p — wherein p is 1-3 and R pa and R pb are selected independently from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo; B represents a C 4-8 saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C 1-6 alkyl, C 1-6 alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C 1-6 alkylamido, which C 1-6 alkyl or C 1-6 alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkyl, hydroxy, C 1-6 alkenoxy, C 1-6 alkoxy, halo, or C 1-6 alkyl, which C 1-6 alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.

  式I的化合物，或其盐或水合物，如下所示：其中X和Y分别选择自氢和芳基，所述芳基未取代或被羟基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、芳基、杂环烷基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷氧基、C1-6烷基、C1-6烷氧基或卤素取代一次或多次，其中烷基或烷氧基基团未取代或被卤素取代一次或多次；m和n独立地为0到3，但要求m和n不能同时为0；A代表单键或为—(CRpaRpb)p—，其中p为1-3且Rpa和Rpb独立选择自氢、C1-6烷基、C1-6烷氧基和卤素，其中烷基或烷氧基基团独立地被卤素取代一次或多次；B代表C4-8饱和或不饱和环，所述环未取代或被C1-6烷基、C1-6烷氧基、芳基、芳氧基、羟基、氧代、卤素、氨基、C1-6烷基氨基、二(C1-6烷基)氨基和C1-6烷酰胺取代一次或多次，其中C1-6烷基或C1-6烷氧基基团未取代或被卤素取代一次或多次，所述芳基未取代或被芳基、杂环烷基、芳氧基、芳基C1-6烷氧基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷基、羟基、C1-6烯氧基、C1-6烷氧基、卤素或C1-6烷基取代一次或多次，所述C1-6烷基可能被卤素取代一次或多次，所述芳基通过单键与所述环相连或与之苯并结合的化合物是ORL-1受体的配体。
• ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
  申请人：Lupin Limited

  公开号：US20150239827A1

  公开（公告）日：2015-08-27

  The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I)

  本发明提供了芳基烷基胺化合物作为钙感受器调节剂（CaSR）。特别地，本文所描述的化合物可用于治疗、管理和/或减轻与钙感受器调节剂（CaSR）调节相关的疾病、疾病、综合症和/或病况的严重程度。本发明还提供了它们的药物组合物和治疗、管理和/或减轻与CaSR调节相关的疾病、疾病、综合症和/或病况的严重程度的方法。本发明还涉及制备本发明化合物的方法。（公式I）